Related Experiment Video
Updated: Oct 10, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
Shuling Wan1,2,3, Yuchuan Ding2,4, Xunming Ji1,2,3
11Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Insights
Ezetimibe combined with statins offers a potent strategy for lowering LDL-C in elderly patients with atherosclerotic vascular disease (ASVD). This combination therapy proves effective across various ASVD subtypes, improving lipid management beyond statins alone.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
- Geriatrics
Background:
- Atherosclerotic vascular disease (ASVD) poses a significant global health challenge in the elderly, characterized by high morbidity and mortality.
- Lowering plasma LDL-C is crucial for ASVD management, yet many patients do not reach target levels with statins alone.
Purpose of the Study:
- To review the efficacy and safety of combining ezetimibe with statins for managing various atherosclerotic vascular disease subtypes.
- To highlight the benefits of this combination therapy in elderly patients with multi-organ atherosclerosis.
Main Methods:
- Systematic review of studies evaluating ezetimibe and statin combination therapy.
- Analysis of efficacy and safety data across different ASVD manifestations.
Main Results:
- Ezetimibe, an inhibitor of cholesterol absorption, enhances LDL-C reduction when used with statins compared to statins monotherapy.
- The combination therapy demonstrates effectiveness in managing coronary artery disease, aortic atherosclerosis, cerebrovascular, and peripheral artery diseases.
Conclusions:
- Ezetimibe plus statins provide a valuable therapeutic option for achieving LDL-C goals in elderly patients with diverse forms of ASVD.
- This combination strategy offers a promising approach for comprehensive atherosclerotic vascular disease management, particularly in older individuals with multi-organ involvement.
Abstract:
It is well known that atherosclerotic vascular disease (ASVD) in the elderly is a global disease with high morbidity, mortality and disability, and plasma LDL-C correction is the most important strategy for ASVD control. However, a large proportion of patients failed to achieve their ideal LDL-C goals after statins use. Ezetimibe, a newly non-statin lipid-lowering agent, is an inhibitor of exogenous cholesterol absorption. Whereby, ezetimibe plus statins may reduce LDL-C more strongly than statins alone. Differed from any other papers published previously, which only involved ezetimibe plus statins for coronary heart disease, the highlight of this paper is to summarize the efficacy and safety of ezetimibe plus statins in all kinds of ASVD subtypes and their related diseases, mainly included aortic atherosclerosis, coronary artery disease, cerebrovascular and peripheral artery diseases. Obviously, this paper is inimitable, which will provide the readers an important reference, especially in treating the elderly with multi-organs atherosclerosis.
More Related Videos
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management
01:30Atherosclerosis I: Introduction
01:23Atherosclerosis IV: Nursing Management
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care